AnaptysBio Inc (NASDAQ:ANAB) has been assigned a consensus rating of “Buy” from the thirteen research firms that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $126.60.
A number of brokerages recently issued reports on ANAB. Stifel Nicolaus set a $124.00 price objective on shares of AnaptysBio and gave the company a “buy” rating in a report on Wednesday, May 8th. Zacks Investment Research lowered shares of AnaptysBio from a “buy” rating to a “hold” rating in a report on Tuesday, May 7th. Cantor Fitzgerald set a $140.00 price objective on shares of AnaptysBio and gave the company a “buy” rating in a report on Tuesday, April 2nd. Wedbush reissued an “outperform” rating on shares of AnaptysBio in a report on Friday, March 1st. Finally, Guggenheim began coverage on shares of AnaptysBio in a report on Friday, February 22nd. They issued a “buy” rating and a $135.00 price objective for the company.
In related news, insider Marco Londei sold 10,060 shares of the company’s stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $73.06, for a total value of $734,983.60. Following the completion of the sale, the insider now owns 32,437 shares of the company’s stock, valued at $2,369,847.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Hamza Suria sold 22,428 shares of the stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $73.76, for a total transaction of $1,654,289.28. Following the transaction, the chief executive officer now directly owns 31,524 shares of the company’s stock, valued at approximately $2,325,210.24. The disclosure for this sale can be found here. Corporate insiders own 14.00% of the company’s stock.
A number of hedge funds have recently made changes to their positions in ANAB. Quantamental Technologies LLC purchased a new position in shares of AnaptysBio in the fourth quarter valued at approximately $38,000. US Bancorp DE boosted its stake in shares of AnaptysBio by 190.4% in the first quarter. US Bancorp DE now owns 970 shares of the biotechnology company’s stock valued at $71,000 after purchasing an additional 636 shares during the period. Diag Capital Management LP purchased a new position in shares of AnaptysBio in the fourth quarter valued at approximately $95,000. SG Americas Securities LLC purchased a new position in shares of AnaptysBio in the fourth quarter valued at approximately $126,000. Finally, Smith Asset Management Group LP purchased a new position in shares of AnaptysBio in the fourth quarter valued at approximately $149,000.
Shares of NASDAQ ANAB traded down $2.08 during mid-day trading on Monday, reaching $71.99. The company’s stock had a trading volume of 2,736 shares, compared to its average volume of 214,994. The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of -28.72 and a beta of 1.98. AnaptysBio has a 1-year low of $54.26 and a 1-year high of $110.00.
AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.82) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.83) by $0.01. Equities research analysts expect that AnaptysBio will post -3.63 earnings per share for the current fiscal year.
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.
Featured Article: Technical Analysis
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.